search
Back to results

Testing of Computer Aided Detection Software for Riverain Medical Group

Primary Purpose

Lung Cancer

Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
Software
Sponsored by
Georgetown University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an observational trial for Lung Cancer focused on measuring Lung Cancer, Chest Radiograph, Computer-aided Detection, Image processing

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • US American Board of Radiology Certified Radiologists in active clinical practice

Exclusion Criteria:

  • Specialists in pulmonary or chest or cardio-pulmonary radiology Prior membership on expert panels for this study who prepared cases Current or recent colleagues or trainees (within 10 years) of the Principal Investigator

Sites / Locations

  • ISIS Imaging Science Research Center, Georgetown University

Arms of the Study

Arm 1

Arm Type

Arm Label

Radiologists

Arm Description

Radiologists who have certification by the American Board of Radiology

Outcomes

Primary Outcome Measures

Improvement in Cancer Detection as Measured by Localized Receiver Operating Characteristic) LROC Changes Under the LROC Curve.
Standard methods for LROC methodology and statistical analysis were used. We are testing two different types of software using different cases, but the same radiologists to control for radiologist differences. LROC is Localized Receiver Operating Characteristic. LROC measures the trade-offs between sensitivity and specificity as radiologists use different levels of suspicion of disease. This analysis is for the software that decreases the visibility of the ribs and clavicles while preserving (and potentially enhancing) the visibility of the lungs and lung diseases. In this case, the level of suspicion recorded was for the radiologist's concern that a finding did or did not represent cancer. Please note that the FDA approved indications for use is to detected nodules that may represent cancer, but in our study scoring for a true finding was based on whether or not the nodule did represent cancer. A larger number, if statistically significant, indicates that that method is better.

Secondary Outcome Measures

Sensitivity and Specificity Using SoftView Software
Sensitivity and specificity were calculated using the radiologists' responses of recommendations for follow-up with CT or biopsy. Truth was whether or not the nodule identified was found to be cancer. Sensitivity is the percentage of correct identification of a positive case (a case with cancer). Specificity is the percentage of negative cases (those without cancer) that were correctly identified as not having cancer. The mean values of 15 radiologists are used.

Full Information

First Posted
May 5, 2008
Last Updated
August 20, 2014
Sponsor
Georgetown University
Collaborators
Riverain Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT00906789
Brief Title
Testing of Computer Aided Detection Software for Riverain Medical Group
Official Title
Testing of Computer Aided Detection Software for Riverain Medical Group
Study Type
Observational

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
June 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Georgetown University
Collaborators
Riverain Technologies

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a clinical trial using retrospective data of two different software devices developed by Riverain Medical Group: Softview and OnGuard 5.0. The two studies will be run concurrently. Riverain Medical Group's computer systems are designed to assist radiologists in their identification of lung cancer on chest radiographs. The current machine received FDA Pre-Market Approval. This is to test two new software approaches.
Detailed Description
In 2000, data was presented to the FDA to demonstrate that a new system for computer analysis could assist radiologists in the detection of small lung cancers on chest radiographs. Radiologists using the system showed a statistically significant improvement in lung cancer detection rate when they used the system, compared to their interpretation of chest radiographs when they did not use the computer system. This study, along with other supporting data, resulted in the FDA giving Pre-Market Approval for the system. The system has undergone several improvements in software and hardware, and it is now intended to test two different software systems to determine whether radiologists using the systems can improve their detection of lung cancer on chest radiographs. One of these systems processes the chest radiograph to decrease the emphasis given to the shadow of the ribs and thereby enhances the ability of radiologists to detect disease in the lungs. The second system performs a series of evaluations on chest radiographs and, based on a complex system of analysis, points to locations on the chest radiograph that contain solitary pulmonary nodules having the characteristics of primary lung cancer or solitary metastases of cancer to the lungs. This will be a test of radiologists to determine the degree of improvement, if any, that results when they interpret chest radiographs that may or may not have cancer, first interpreted without the computer and, second, with the images output by the software.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer
Keywords
Lung Cancer, Chest Radiograph, Computer-aided Detection, Image processing

7. Study Design

Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Radiologists
Arm Description
Radiologists who have certification by the American Board of Radiology
Intervention Type
Behavioral
Intervention Name(s)
Software
Other Intervention Name(s)
SoftView 2.0, OnGuard 5.1
Intervention Description
This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
Primary Outcome Measure Information:
Title
Improvement in Cancer Detection as Measured by Localized Receiver Operating Characteristic) LROC Changes Under the LROC Curve.
Description
Standard methods for LROC methodology and statistical analysis were used. We are testing two different types of software using different cases, but the same radiologists to control for radiologist differences. LROC is Localized Receiver Operating Characteristic. LROC measures the trade-offs between sensitivity and specificity as radiologists use different levels of suspicion of disease. This analysis is for the software that decreases the visibility of the ribs and clavicles while preserving (and potentially enhancing) the visibility of the lungs and lung diseases. In this case, the level of suspicion recorded was for the radiologist's concern that a finding did or did not represent cancer. Please note that the FDA approved indications for use is to detected nodules that may represent cancer, but in our study scoring for a true finding was based on whether or not the nodule did represent cancer. A larger number, if statistically significant, indicates that that method is better.
Time Frame
Three days of experiment over 3-5 months, varied by participant
Secondary Outcome Measure Information:
Title
Sensitivity and Specificity Using SoftView Software
Description
Sensitivity and specificity were calculated using the radiologists' responses of recommendations for follow-up with CT or biopsy. Truth was whether or not the nodule identified was found to be cancer. Sensitivity is the percentage of correct identification of a positive case (a case with cancer). Specificity is the percentage of negative cases (those without cancer) that were correctly identified as not having cancer. The mean values of 15 radiologists are used.
Time Frame
Three days of experiment over 3-5 months, varied by participant
Other Pre-specified Outcome Measures:
Title
Difference in the Area Under the LROC Curve Comparing OnGuard 1.0 and OnGuard 5.1
Description
This reports the comparison of the detection of lung nodules that were proven to represent lung cancers. It compares the results of two versions of computer-aided detection software: OnGuard 1.0 from 2001 and OnGuard 5.1 from 2009. The results represent the responses of radiologists when they use one or the other types of software. To compare radiologists' results with the two types of software, the measurement analyzed was the difference in the areas under the localized receiver operating characteristic curve (LROC). The results from the 15 participating radiologists were averaged (mean value). The area under the LROC curve is a measure of the trade-offs between sensitivity and 1-specificity that occurs as the level of certainty of a positive finding changes. It is normally reported as a decimal without units. In this study dsign, a lower number indicates that the new method (OnGuard 5.1), if statistically significant, if better.
Time Frame
5 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: US American Board of Radiology Certified Radiologists in active clinical practice Exclusion Criteria: Specialists in pulmonary or chest or cardio-pulmonary radiology Prior membership on expert panels for this study who prepared cases Current or recent colleagues or trainees (within 10 years) of the Principal Investigator
Study Population Description
Radiologists in active clinical practice who are not subspecialists in chest radiology
Sampling Method
Non-Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew T. Freedman, MD, MBA
Organizational Affiliation
Georgetown University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ben Lo, Ph.D.
Organizational Affiliation
Georgetown University
Official's Role
Study Director
Facility Information:
Facility Name
ISIS Imaging Science Research Center, Georgetown University
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20057
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21493789
Citation
Freedman MT, Lo SC, Seibel JC, Bromley CM. Lung nodules: improved detection with software that suppresses the rib and clavicle on chest radiographs. Radiology. 2011 Jul;260(1):265-73. doi: 10.1148/radiol.11100153. Epub 2011 Apr 14.
Results Reference
derived

Learn more about this trial

Testing of Computer Aided Detection Software for Riverain Medical Group

We'll reach out to this number within 24 hrs